Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses

Open access
Catalá-López, Ferrán, Macías Saint-Gerons, Diego, González-Bermejo, Diana, Rosano, Giuseppe M., Davis, Barry R., Ridao, Manuel, Zaragoza, Abel, Montero-Corominas, Dolores, Tobías, Aurelio, de la Fuente-Honrubia, César, Tabarés-Seisdedos, Rafael, Hutton, Brian · 2016 · PLOS Medicine

Abstract

BACKGROUND: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. METHODS AND FINDINGS: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary endpoints were cardiovascular mortality, myocardial infarction, and stroke-singly and as a composite endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as a composite endpoint, progression of renal disease. Secondary endpoints were angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 participants), with a total of 14 different regimens, were pooled using network meta-analyses. When compared with ACE inhibitor, no other RAS blocker used in monotherapy and/or combination was associated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus ACE inhibitor (1.32; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73-1.38). For the risk of progression of renal disease, no significant differences were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65-1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78-1.84). No significant differences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine. Findings were limited by the clinical and methodological heterogeneity of the included studies. Potential inconsistency was identified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for these single endpoints. CONCLUSIONS: In adults with diabetes, comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. Compared with monotherapies, the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outcomes. Clinicians should discuss the balance between benefits, costs, and potential harms with individual diabetes patients before starting treatment. REVIEW REGISTRATION: PROSPERO CRD42014014404.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001971

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Evidence network of all treatment comparisons for all studies. Lines represent direct comparisons within randomized controlled trials. The size of nodes is proportional to the number of randomized participants (sample size), and the width of the lines is proportional to the number of trials comparing each pair of treatments. Nodes in green represent RAS blockers (in monotherapy and/or combination therapies). Nodes in blue represent other control arms included in the evidence networks to preserve randomization. ACEi, ACE inhibitor; DRi, DR inhibitor.
Fig 1 Evidence network of all treatment comparisons for all studies. Lines represent direct comparisons within randomized controlled trials. The size of nodes is proportional to the number of randomized participants (sample size), and the width of the lines is proportional to the number of trials comparing each pair of treatments. Nodes in green represent RAS blockers (in monotherapy and/or combination therapies). Nodes in blue represent other control arms included in the evidence networks to preserve randomization. ACEi, ACE inhibitor; DRi, DR inhibitor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 103 references

Cited by

See all 109

Metadata

Authors
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., Tabarés-Seisdedos, R., & Hutton, B.
Affiliations
  • Universitat de València (ES)
  • IRCCS San Raffaele Roma (IT)
  • The University of Texas Health Science Center at Houston (US)
  • Agencia Española de Medicamentos y Productos Sanitarios (ES)
  • University of Ottawa (CA)
Corresponding author
Catalá-López, Ferrán
Venue
PLOS Medicine
Published
2016-03-08
Volume
13
Issue
3
Pages
e1001971
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2292998606
Cited by
109
References
103
Citations by year
2026: 3 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 18 · 2019: 12 · 2018: 16 · 2017: 10 · 2016: 2
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Digital Collections of Colorado (Colorado State University) (submittedVersion)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
Funders
  • Generalitat Valenciana (PROMETEOII/2015/021)
  • Centro de Investigación Biomédica en Red de Salud Mental
  • INCLIVA Instituto de Investigación Sanitaria
  • Canadian Institutes of Health Research
  • Instituto de Salud Carlos III (PROMETEOII/2015/021, PI14/00894, PI14/)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
renin-angiotensin system blockade, diabetes mellitus, ACE inhibitors, angiotensin receptor blockers, renin inhibitors, cardiovascular outcomes, renal outcomes, end-stage renal disease, cardiovascular mortality, myocardial infarction, stroke, heart failure hospitalization, angina pectoris, combination therapy, all-cause mortality, serum creatinine
MeSH terms
Renin Inhibitors, Adult, Angina Pectoris, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Heart Failure, Hospitalization, Humans, Kidney Failure, Chronic, Myocardial Infarction, Renin-Angiotensin System, Stroke, Diabetes Complications, Renal Insufficiency, Chronic, Secondary Prevention, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. https://app.cochat.ai/papers/10.1371/journal.pmed.1001971
The paper
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., Tabarés-Seisdedos, R., & Hutton, B. (2016). Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1001971

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.